Neuroimmunology as a separate discipline has its roots in the fields of neurology, neuroscience and immunology. Early studies of the brain by Golgi and Cajal, the detailed clinical and neuropathology studies of Charcot and Thompson's seminal paper on graft acceptance in the central nervous system, kindled a now rapidly expanding research area, with the aim of understanding pathological mechanisms of inflammatory components of neurological disorders. While neuroimmunologists originally focused on classical neuroinflammatory disorders, such as multiple sclerosis and infections, there is strong evidence to suggest that the immune response contributes to genetic white matter disorders, epilepsy, neurodegenerative diseases, neuropsychiatric disorders, peripheral nervous system and neuro-oncological conditions, as well as ageing. Technological advances have greatly aided our knowledge of how the immune system influences the nervous system during development and ageing, and how such responses contribute to disease as well as regeneration and repair. Here, we highlight historical aspects and milestones in the field of neuroimmunology and discuss the paradigm shifts that have helped provide novel insights into disease mechanisms. We propose future perspectives including molecular biological studies and experimental models that may have the potential to push many areas of neuroimmunology. Such an understanding of neuroimmunology will open up new avenues for therapeutic approaches to manipulate neuroinflammation.
Introduction
Neuroimmunology encompasses fundamental and applied biology, immunology, chemistry, neurology, pathology, psychiatry and virology of the central nervous system (CNS). Scientists in the field study the interactions of the immune and nervous system during development, homeostasis and response to injuries with the major aim of developing approaches to treat or prevent neuroimmunological diseases.
The immune system has been generally regarded as autonomous and the brain protected by the blood-brain barrier, (BBB) and in the words of Rudyard Kipling (Barrack-room ballads , 1892), 'never the twain shall meet'. In the past decades these dogmas have been strongly challenged and dispelled with the wealth of evidence showing that not only does the nervous system receive messages from the immune system, but that signals from the brain regulate immune functions that subsequently control inflammation in other tissues [1] . Communication between the immune system and the CNS is exemplified by the finding that many molecules associated with the immune system are widely expressed and functional in the nervous system and vice versa. Cross-talk between microglia and neurones is known to be essential for maintaining homeostasis, yet such cross-talk also occurs between oligodendrocytes and microglia [2] . Disturbance in this communication due to peripheral infections in mice are known to trigger microglia activation and augment neurodegeneration [3] . Similarly, recent experimental studies show that maternal infections lead to long-term changes in microglia and abnormal brain development in the offspring [4, 5] .
Here, we review the developments in neuroimmunology since its roots in the first descriptions of immunological processes and neurological diseases, as well as the development of technologies and clinical trials for such diseases. Important events are given in major timelines or eras, along with the Nobel Prizes considered relevant by their impact on the field of neuroimmunology. The review also includes a perspective on the future of neuroimmunology that should herald prospective approaches to understanding these diseases, and we address several outstanding questions in the field. The long-term goal of this rapidly developing field of neuroimmunology is to further the understanding of how immune responses shape the nervous system during development and ageing, how such responses lead to neurological diseases, and ultimately to develop new pharmacological treatments. These aspects are thus the major topics of the International Society of Neuroimmunology meetings (ISNI) (Fig. 1 ) and the educational topics of the global schools in neuroimmunology.
Historical beginnings
The first descriptions of many neuroinflammatory disorders come from personal notes, early authors and diarists. The earliest report purported to be MS was in an Icelandic woman (in approximately 1200) and Saint Lidwina of Schiedam (1380-1433), while the detailed personal diaries of Sir Augustus d'Esté, born in 1794 (grandson of King (Fig. 2) , as well as in early medical documents and diaries descriptions of encephalitis. Neuroinflammatory disorders were also documented in (albeit) fictional characters in novels such as those by Charles Dickens [47, 48] . Early detailed descriptions of many neurological diseases expanded in the early 1800s (Fig. 2) , due in part to Jean-Martin Charcot (1825-1893), who systematically identified many neurological diseases including Charcot-Marie-Tooth, MS, Parkinson's disease (PD; only later in 1872 was Parkinson credited for his earlier description, Fig. 2 ) and amyotrophic lateral sclerosis (ALS), by linking the clinical disease in patients with detailed studies of the anatomy and microscopy of diseased tissues [49] . The link between neurology and immunology gained momentum with the refinement of the microscope and development of staining techniques to allow detailed studies of tissue. For example, the identification of different types of glial cells in the CNS and peripheral nervous system History of Neuroimmunology
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(PNS) was aided by the use of chemicals to enhance the microscopic visibility of nerve cells [50, 51] , approaches for which Camillo Golgi and Santiago Ramon y Cajal received the Nobel Prize for Medicine in 1906 (Table 2) . It was also with these new staining techniques that Alois Alzheimer identified the pathology underlying dementia that later became known as Alzheimer's disease (AD) (1906) [52] , and allowed Dawson to perform detailed microscopic examinations of MS (1916) [53] showing inflammation around blood vessels in CNS lesions. Purkinje is credited for the first descriptions of neurones in 1837 [54] , and only later did Golgi describe glial cells (1871), although Virchow had introduced the name 'neuroglia' and created the concept that nerve cells are held together by 'glia' (meaning glue) in 1856 [55] . Alongside the descriptions of neurological disease, various aspects of immunology were also investigated (Fig. 2) . Metchnikoff revealed the rudimentary immune cells in freshwater starfish (1880) [56] , and used the term 'phagocytosis', which became the basis of his research for which he was awarded the Nobel Prize in 1908 with Paul Ehrlich for discovery of blood leucocytes (Table 2) . Later, Rio-Hortega showed that cells in the brain (microglia) were able to phagocytose (1919) [57] . In the same year, Jules Bordet was awarded the Nobel Prize for identifying factors (antibodies) in blood arising after vaccination [58] , although it was not until 70 years ago that B cells were found to be important producers of antibodies in 1948 [59] .
Immunology at the time was focused on the vaccine development for infectious diseases after the published work on the first vaccine for smallpox by British physician Edward Jenner in 1796 [60] . More relevant for the neuroimmunological field was the discovery of the vaccine for the neurotrophic rabies virus by Louis Pasteur (1885) [61] and the vaccine for polio by Jonas Edward Salk (1953) [62] . Importantly, Pasteur used dried virus-infected rabbit spinal cord for immunization which occasionally induced a postvaccine encephalomyelitis in humans. That the disease did not reflect rabies indicated that brain components in the vaccine were antigenic. In the 1940s adjuvants were developed to potentiate vaccines, and several vaccines as well as infections have been linked to neuroinflammatory diseases such as, for example, e.g. MS and acute disseminated encephalomyelitis (ADEM) ( Table 1 ). The serendipitous finding of post-rabies vaccination encephalitis was later exploited for immunization strategies to deliberately induce experimental autoimmune diseases (Fig. 2) (Table 2) .
1960-1980
Further to the identification and description of diseases, this era prompted the development of precise criteria for diagnosis of neuroinflammatory diseases, as well as examining the pathological mechanisms underlying disease and testing therapeutic approaches (Fig. 3) . Technically, the development of computed tomography scans, positron emission spectroscopy (PET) and magnetic resonance imaging (MRI) allowed the first images of living brain, revolutionizing the diagnosis of neuroinflammatory diseases and allowing non-invasive monitoring of disease progression as well as response to therapy. 
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There was a surge in discoveries related to antibodies after the antibody structure was discovered (1959) [63] . In this era associations were made linking antibodies to diseases such as MG and other neuroinflammatory diseases [64] . For some diseases the target of the antibodies were identified [65] , and the impact of pathogenic antibodies shown in vitro [66] . A key development in the immunology field was the generation of monoclonal antibodies (mAb) [67] . Not only were mAb key to the development of assays such as enzyme-linked immunosorbent assay and other techniques key to linking immune cells to neurological diseases [68] , this advancement also allowed development of specific therapeutic approaches in which mAb were designed to block or deplete specific cells of the immune system.
The involvement of immune responses in neurological diseases prompted new approaches to treat disease and development of animal models of human diseases. While adjuvants developed in the 1940s were essential for inducing clinical disease in the case of experimental autoimmune encephalitis (EAE) [69] and experimental autoimmune neuritis (EAN), injection of antibodies to acetylcholine receptor (AchR) and from patients with myasthenia gravis (MG) induced experimental disease in rabbits. The therapy used for antibody-mediated diseases included plasma exchange [70] , while broad immunosuppressive approaches, e.g. adrenocorticotrophic hormone, were implemented for MS [Food and Drug Administration (FDA)-approved in 1978].
Study of the immune system differentiated between cellular and humoral immunity and recognized T and B cell interactions, as well as the discovery of the first interleukins. Key to further developments in immune-mediated diseases was Zinkernagel and Doherty's finding (1974) that elimination of virus-infected cells killer T cells required not only to recognize the virus but also the major histocompatibility complex (MHC) molecule of the host [71] . Around this time the realization grew that cells later named as dendritic cells, due to their morphology, were intricately linked with adaptive immune responses, a notion that would later earn Steinman the Nobel Prize [72] . Studies in this era supporting Cajal's idea, that glia assist neurones, were aided by the development of the electron microscope and electrophysiological studies, although how this impacted on neuroinflammatory disease was as yet unknown.
1981-2000
This era saw major steps in putting neuroimmunology on the map as a new field with the launch of If the previous era was dedicated to the role of antibodies in disease for which Tonegawa received the Nobel Prize in 1987 (Table 2 ) [73] , this era was that of T cells in neuroimmunology and the recognition of the importance of innate immunity (Fig. 3) . Following Doherty and Zinkernagel's discovery in 1974, for which they were awarded the Nobel Prize in 1996, major steps were made in identifying the T cell receptor (1983) (1984) (1985) (1986) (1987) [74, 75] (Table  2) , classification of T cells (1986) [76] , the role of MHC peptide complex in triggering T cell responses (1991) [77] and how T cells are regulated (1995) [78] or modified using altered peptide ligands (1998) [79] . Models also made use of the emerging field of transgenic mice designed to express human proteins such as human leucocyte antigens (HLA), T cells expressing specific T cell receptors (TCRs), markers such as green fluorescent protein (GFP) to allow tracking of cells or generated to lack specific molecules (knock-out or deficient mice). Many of the studies examining the pathogenic role of T cells focused on the EAE model of MS (1981) (1982) (1983) (1984) [80] [81] [82] although inflammation was also reported in depression (1983) [83] and neurodegenerative diseases, e.g. AD, which up to that point had been widely assumed to be due to neuronal degeneration. While many studies focused on immune-mediated damage, studies also revealed the importance of the immune response in shaping neuronal development. For example, while microglia were reported to be crucial for synaptic pruning, new studies from the Shatz laboratory revealed that neuronal expression of MHC class I was key to longterm structural and synaptic modifications [84] .
The focus on pathogenic T cells in EAE models of MS increased and experiments using antibodies to block TCRs were performed [85, 86] . Further studies highlighted the importance of other myelin antigens as targets for the demyelinating response and induction of chronic relapsing clinical disease to model the disease course in MS more clearly [87] .
Although T cells were at the forefront of many studies, therapeutic approaches targeting pathogenic antibodies such as trials using intravenous immunoglobulin (IVIg) in GBS, or use of therapeutic mAB to block adhesion molecules on immune cells, revealed the importance of cell trafficking across the BBB [88] . Although such approaches were effective in animal models, blocking immune cell entry in the CNS in humans had serious side effects. Other strategies focused on repairing damage in the nervous systems were examined. These strategies included transplanting oligodendrocyte progenitor cells for remyelination [89] and stem cells that, although originally designed to replace damaged cells, they were later recognized to be neuroprotective via the release of growth factors and immune modulatory molecules (i.e. therapeutic plasticity) [90] .
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This era saw the emergence of the human immunodeficiency virus (HIV), the isolation of HTLV-1-like retrovirus from tropical spastic paraparesis cases, the link between Campylobacter jejuni infection and GBS and the Nobel Prize to Prusiner for his studies on prions as new infectious particles promoting neurological disease (Table 2) . These findings clearly highlighted the role of infectious agents in triggering neuroinflammatory disorders, although it was unclear how the different infections triggered disease. One innovative concept at the time was proposed by Janeway (1989) [91] , suggesting that microbes act via receptors on innate immune cells. Only later was this concept validated by the discovery of Toll-like receptors (TLR) and other innate receptors, as well as dendritic cells (Nobel Prize: Beutler, Hoffman, Steinman 2011). Further revelations were made in 1994, when Matzinger proposed the 'danger model' (1994) to include the concept that changes in the host's tissues due to 'dangerous' situations, i.e. trauma or disease, could also activate innate immunity [92] .
Another technological leap during this era was the use of genetic engineering that enabled the generation of mice expressing antigen-specific TCR, such as against the myelin basic protein, and humanized mice expressing certain HLA haplotypes in an attempt to understand how human genes contributed to neuroinflammmatory diseases.
2001-2018
Accumulating evidence during the last two decades shows that immune senescence is associated with late-onset neurodegenerative diseases such as AD, PD, spinal cerebellar ataxia, ALS and Huntington's disease, thus broadening the range of diseases falling within the neuroimmunology field (Table 1) . Further evidence that the immune response is also key to neuronal development was highlighted by the finding that the complement component C1q is expressed by synapses of postnatal but not adult neurones [93] (Fig. 4) . Studies in this era have also expanded ideas of how microbes, such as the newly emerging Zika virus, the re-emergence of Ebola and the gut microbiome, influence susceptibility to neuroinflammatory disease. In line with this, clinical trials have highlighted the need to develop more specific approaches in neuroimmune diseases other than broad immunosuppression or blocking cells from entering into the CNS, in order to avoid the emergence of opportunistic infections. Thus, specific approaches such as cell depletion therapies (e.g. of B cells in MS), tolerance-inducing strategies and the use of stem cells have been a major focus in MS, while gene therapy approaches have been initiated in an attempt to correct genetic mutations in ALS [94] (Fig. 4) .
Probing neuroinflammatory diseases has been aided with improved higher-resolution MRI, single photon emission computed tomography and PET ligands [95, 96] , and optical coherence tomography to visualize the progression of disease in patients and for some modes the contribution of inflammation. Similarly, in-vivo optical imaging, for example of GFP-labelled T cells, glia or transplanted human induced pluripotent stem cells (iPSC), in experimental models has greatly influenced our knowledge of the cross-talk between the immune and nervous systems [97] .
Although mainly limited to in-vitro and animal studies, genetic modification has proved to be an indispensable tool to study gene function in normal development and disease and has yielded several Nobel Prizes in this area (2006, Fire and Mello; 2007, Capecchi, Evans, Smithies). Breakthroughs in this era include the generation of human iPSCs for which Gurdon and Yamanaka received the Nobel Prize in 2012; gene-targeting approaches and genome-editing tools, the most effective for interrogation of neuroimmune disease being the CRISPR/Cas9 system (derived from clustered regularly interspaced short palindromic repeats) originating from early discoveries in bacteria [98] . While yet to prove applicable to human disorders, such gene editing has allowed genetic manipulation of iPSC from humans, ALS models and elimination of viral infections by targeting viral genomes.
Future perspectives
While current therapies aim to modulate neuroinflammation arising during the disease, future approaches should aim at disease prevention. For some diseases, the aetiological agents are known, and thus vaccination strategies are key for disease prevention. In other cases, the specific genes or environmental agents triggering disease require clarification. Prophylactic approaches for genetic disorders could exploit genetic modification during development, while cell therapy strategies may aid regeneration of the damaged nervous system. Exploitation of infections agents may also be beneficial, as demonstrated by the recent clinical trial using a non-pathogenic poliovirus for treating glioblastomas [99] .
For disease prevention, rapid and specific diagnosis as well as adequate ways to monitor the disease course and response to therapy are crucial. Thus, advancements in biomarker research will be key to faster diagnosis and more efficient monitoring in clinical trials, speeding up drug development and reducing costs. Biomarkers of neuroimmunological diseases may include markers of BBB disruption, demyelination, oxidative stress and excitotoxicity, axonal/neuronal damage, gliosis, remyelination and repair, but should also focus on markers of altered immune function such as cytokines, chemokines, antibodies, adhesion molecules, antigen presentation and changes in cellular subpopulations [100] . Ideally, detection and collection of new biomarkers will be minimally invasive, specific for the disease and reflect response to therapy Additionally, well-characterized tissue biobanks will be crucial to these advancements in biomarkers.
Another important aspect of future neuroimmunology research and developments will be in disease modelling. The highly effective CRISPR/cas9 system will allow precision engineering of the genome, and has the potential to speed up the generation of transgenic animal models, generating single-gene mutations in adult animals. Model systems making use of iPSCs from patients will also allow better translation of fundamental research data to the clinic. Further advances in CRISPR/cas9 or similar systems to increase transgene efficiency or to regulate gene expression using inducible expression systems will allow genes to be regulated once gene editing is completed. Such approaches will herald better treatments in the form of personalized medicine, gene editing (taking into account the ethical issues) and improved clinical trial design. 
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The increase in data generated by next-generation sequencing is expected to aid identification of genetic variants in neuroimmunological diseases. Such data are already contributing to designing algorithms, development of pharmacogenomics and personalized medicine. These approaches will be fundamental in reducing risks in drug development by avoiding adverse drug reactions, and minimizing cost by limiting drug administration solely to those patients who will benefit [101] . While drug discovery is increasingly costly and prolonged, artificial intelligence (AI) may be key to reversing this trend. AI will use previously collected data and molecular dynamic predictions to reduce the number of compounds to be screened, repurpose compounds, predict interactions between compounds and their target and refine clinical trial populations [102] . Advancements in targeted drug delivery will also reduce side-effect profiles of compounds and aid in those compounds that will readily cross the BBB [103] . Both Big Pharma and academia have the potential to increase drug discovery efficiency by embracing AI, pharmacogenomics, personalized medicine and targeted drug delivery to provide future treatments of neuroimmunological diseases.
Conclusions
The field of neuroimmunology has evolved from early studies recognizing that immune responses are present in the CNS and PNS during disease, to sophisticated approaches for manipulation of the immune system. The list of neuroimmune diseases has expanded from the prototypical cases of MS, GBS and MG to incorporate diseases considered to be purely neurological such as AD, PD, ALS as well as behavioural and mood disorders. Neuroimmunology has evolved to encompassed less disease-orientated fields by addressing how the immune system impacts upon the developing nervous systems during pregnancy, how neural stem cells play an immune regulatory role, the contribution of immune-senescence to ageing, how microbiota influence the immune system, and how this impacts upon development and susceptibility to neurological diseases.
Understanding the delicate balance between the beneficial and pathological effects of the immune system with neuronal development and diseases has already allowed the development of rational approaches for treating neuroimmune disorders. Further advances are expected to address the following points.
How pathogenic (auto)antibodies arise and how they contribute to immune-mediated neurological disorders
While the source of pathogenic antibodies in paraneoplastic neurological syndrome (PNS) are well described, a significant number of neurological diseases in which pathogenic antibodies directed to neuronal structures are not related to cancer. Uncovering how these antibodies arise, how they enter the nervous systems and approaches to inhibit antibody formation will be key to developing effective therapeutic approaches.
The role of memory B cells in autoimmune diseases
For several autoimmune disorders, e.g. MS, rheumatoid arthritis and Graves' disease, among others, an association has been made between Epstein-Barr virus (EBV) and development of disease. The recent awareness that effective therapies target memory B cells makes the hypothesis that EBV triggers autoreactive B cells and/or antibodies is very compelling. Exactly how EBV triggers autoimmune neurological diseases will be an important step in understanding neuroimmunological diseases such as MS.
Inflammaging and neurological diseases
The term 'inflammaging' has been used to describe the chronic, low-grade inflammation associated with ageing. Senescence in the immune and nervous systems covers a multitude of factors, including lowered response to vaccination, decline in effective autophagy and increased susceptibility to cancer and autoimmune diseases. Why such changes occur will be aided by studying healthy aged cohorts of different backgrounds and races and highlight how environmental factors such as diet, gut microbiota or genes and lifestyle contribute to the immune imbalance associated with 'inflammaging'. A key question will thus be: 'Can we manipulate the immune response to combat the effects of ageing?'.
Neuroimmunology of pregnancy and development
Maternal stress or infections during pregnancy have been linked to impaired cognitive development and psychiatric disorders in the offspring. The recent emergence of Zika virus has underscored not only how the brain may be shaped by infections during development, but that such infections may predispose to autoimmune diseases later in life. A future challenge will thus be to understand how maternal immune factors, including immune cells and cytokines, influence brain development in utero and modulate the beneficial factors to enhance brain development to prevent and limit the detrimental effects of the immune system that may contribute to behavioural and mood disorders.
Human stem cell technology and personalized medicine
The advances in reprogramming somatic cells into iPSCs has allowed the culture of patient-specific stem cells, e.g. neuronal stem cells (NSC), to study the disease specific pathways. This technology will allow the development of E. Nutma et al.
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human in-vitro models to study disease and patient-specific pathways. More importantly, these models should also allow approaches to modulate disease-specific factors aiding personalized medicine. For some neuroimmunological diseases the use of NSC has already proved effective in experimental settings to not only repair the nervous system but examine an unexpected trait by which NSC modulate immune responses. While in its infancy, gene-editing approaches are expected to develop to the point that genetic neurological diseases may be treatable and modulate the immune and nervous systems to combat neuroimmunological disease, and in the meantime allow standardization of iPSC cells.
